Peer-influenced content. Sources you trust. No registration required. This is HCN.

Hematology, ASH Education ProgramTreatment of CML in Pregnancy

Today, it is possible to safely treat CML throughout pregnancy with little danger to the unborn child, as TKIs can now be safely administered during the later stages of pregnancy, according to new research. After beginning or continuing TKI therapy, a sizable majority of patients can be managed by observation alone, and disease control can be attained. IFN-α may be given in any trimester with little harm to the fetus if active treatment is necessary. Most essential, however, is a multidisciplinary strategy to offer clear and concise guidance to enable both the mother and the family to participate in the decision-making process.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form